| Clinical data | |
|---|---|
| Other names | PEAQX, NVP-AAM077 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H17BrN3O5P |
| Molar mass | 454.217 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
PEAQX is a competitiveantagonist at theNMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potentanticonvulsant in animal tests.[2]